ArticleMedicine2025
Exploring the positive association of blood lipid levels with prostate cancer risk and their relationship to pathological features in the Chinese population.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Correlation between serum triglycerides and prostate cancer risk in Chinese men: a meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Presently, the majority of investigations into the effects blood lipids on prostate cancer (PCa) primarily involve Western populations. Our study endeavors to investigate the impact of blood lipid levels on the risk of PCa among the Chinese population and to elucidate their potential association with the pathological characteristics of PCa. This study drew data from a dataset for early warning of PCa from the China National Population Health Science Data Center, encompassing 2624 patients who had undergone prostate biopsy. We utilized binary logistic regression to assess the ability of blood lipid levels to distinguish between PCa and non-PCa, as well as to differentiate clinically significant prostate cancer (csPCa) from non-PCa. Additionally, we assessed the ability of these lipid markers to predict whether the Gleason Grade (GG) would be upgraded or downgraded following radical prostatectomy compared to the biopsy GG. Furthermore, ordered multiclass logistic regression was employed to explore the relationship between these indicators and GG. In the Chinese population, triglycerides (P = .004; OR: 1.344; 95% CI: 1.201-1.503), low-density lipoprotein cholesterol (P < .001; OR: 1.314; 95% CI: 1.200-1.439), and apolipoprotein A1 (P < .001; OR: 2.451; 95% CI: 1.714-3.504) were identified as independent risk factors for predicting PCa. Additionally, triglycerides (P = .013; OR: 1.156; 95% CI: 1.031-1.295) and apolipoprotein A1 (P < .001; OR: 2.580; 95% CI: 1.809-3.680) were found to be independent risk factors for predicting csPCa. Our study demonstrated a positive association between blood lipid levels and PCa risk in the Chinese population, highlighting the potential utility of blood lipids as biomarkers for PCa. In male individuals with a familial predisposition to PCa or other recognized risk factors for PCa, the assessment of blood lipid levels can be incorporated as an auxiliary biomarker in the routine health screening protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.